About: Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions
Creator	Kobayashi, Makiko Suzuki, Fujio Takei, Miwa Herndon, David Pollard, Richard
source	Elsevier; Medline; PMC
abstract	Abstract In association with the systemic inflammatory response syndrome (SIRS), anti-inflammatory response syndrome is commonly manifested in patients with trauma, burn injury, and after major surgery. These patients are increasingly susceptible to infection with various pathogens due to the excessive release of anti-inflammatory cytokines from anti-inflammatory effector cells. Recently, CC-chemokine ligand 2 (CCL2) found in the sera of mice with pancreatitis was identified as an active molecule for SIRS-associated anti-inflammatory response manifestation. Also, the inhibitory activity of glycyrrhizin (GL) on CCL2 production was reported. Therefore, the effect of GL on SIRS-associated anti-inflammatory response manifestation was investigated in a murine SIRS model. Without any stimulation, splenic T cells from mice 5 days after SIRS induction produced cytokines associated with anti-inflammatory response manifestation. However, these cytokines were not produced by splenic T cells from SIRS mice previously treated with GL. In dual-chamber transwells, IL-4-producing cells were generated from normal T cells cultured with peripheral blood polymorphonuclear neutrophils (PMN) from SIRS mice. However, IL-4-producing cells were not generated from normal T cells in transwell cultures performed with PMN from GL-treated SIRS mice. CCL2 was produced by PMN from SIRS mice, while this chemokine was not demonstrated in cultures of PMN from SIRS mice treated with GL. These results indicate that GL has the capacity to suppress SIRS-associated anti-inflammatory response manifestation through the inhibition of CCL2 production by PMN.
has issue date	2006-09-30(xsd:dateTime)
bibo:doi	10.1016/j.cyto.2006.10.002
bibo:pmid	17113306
has license	els-covid
sha1sum (hex)	8ef466cd0925e7fcbb1be2629a52fb02f4ee91f4
schema:url	https://doi.org/10.1016/j.cyto.2006.10.002
resource representing a document's title	Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions
has PubMed Central identifier	PMC7129928
has PubMed identifier	17113306
schema:publication	Cytokine
resource representing a document's body	covid:8ef466cd0925e7fcbb1be2629a52fb02f4ee91f4#body_text
is schema:about of	named entity 'Therefore' named entity 'effector cells' named entity 'cytokines' named entity 'patients' named entity 'activity' named entity 'mice' named entity 'SIRS' named entity 'SIRS' named entity 'mice' named entity 'ASSOCIATION' named entity 'ASSOCIATED WITH' named entity 'CELLS' named entity 'MANIFESTATION' named entity 'T CELLS' named entity 'INHIBITION' named entity 'EFFECT' named entity 'IDENTIFIED' named entity 'SPLENIC' named entity 'MOLECULE' named entity 'BURN INJURY' named entity 'PATIENTS' named entity 'PMN' named entity 'TRAUMA' named entity 'MICE' named entity 'NORMAL T CELLS' named entity 'CELLS CULTURED' named entity 'SYNDROME' named entity 'SYSTEMIC INFLAMMATORY RESPONSE SYNDROME' named entity 'DUE TO' named entity 'VARIOUS' named entity 'INVESTIGATED' named entity 'EXCESSIVE' named entity 'CHAMBER' named entity 'GENERATED' named entity 'ACTIVE' named entity 'MANIFESTED' named entity 'POLYMORPHONUCLEAR NEUTROPHILS' named entity 'RECENTLY' named entity 'CULTURES' named entity 'SUPPRESS' named entity 'CCL2' named entity 'TREATED' named entity 'MODEL' named entity 'PERFORMED' named entity 'GLYCYRRHIZIN' named entity 'RELEASE' named entity 'ASSOCIATED' named entity 'SUSCEPTIBLE' named entity 'ANTI-INFLAMMATORY RESPONSE' named entity 'PRODUCING' named entity 'LIGAND' named entity 'MAJOR SURGERY' named entity 'INHIBITORY ACTIVITY' named entity 'REPORTED' named entity 'TREATED WITH' named entity 'INDUCTION' named entity 'GLYCYRRHIZIN' named entity 'REACTIONS' named entity 'LIKE' named entity 'ASSOCIATION' named entity 'MANIFESTATIONS' named entity 'ANTI-INFLAMMATORY' named entity 'SYSTEMIC INFLAMMATORY RESPONSE SYNDROME' named entity 'THESE' named entity 'SERA' named entity 'STIMULATION' named entity 'PANCREATITIS' named entity 'PATHOGENS' named entity 'FOUND' named entity 'CHEMOKINE' named entity 'CCL2 PRODUCTION' named entity 'PERIPHERAL BLOOD' named entity 'DUAL' named entity 'NOT DEMONSTRATED' named entity 'MURINE' named entity 'ANTI-INFLAMMATORY' named entity 'DAYS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software